BioSpace News Archive

A multinational tobacco products manufacturing company recently selected ArisGlobal’s LifeSphere® MultiVigilance 10 for their global safety vigilance needs

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will present at the 9th Annual SVB Leerink Global Healthcare Conference.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the HTG EdgeSeq Mouse mRNA Tumor Response Panel as a way to identify endogenous targets of cardiac fibrosis as reported in the September 2019 issue of Nature.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®.

Encoded Therapeutics, Inc. (Encoded), a precision gene therapy company, today announced the appointment of Salvador Rico, M.D., Ph.D., as chief medical officer and the promotion of Martin Moorhead, Ph.D., to chief technology officer.

Company plans to exceed that amount in 2020 to help address housing insecurities and promote community health improvement

LimaCorporate has already announced its intention to enter the digital space and drive the development of a digital platform to provide surgeons with innovative solutions which would help them deliver improved outcomes with a sustainable economic model through the milestone-based acquisition of TechMah Medical.

Incyte announced that it will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. ET in Boston.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the Company’s Phase 2a study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients.

Feb. 11, 2020 13:00 UTC ProtoKinetix Files for Patent Protection for the Use of AAGP ® in Transplant Medicine MARIETTA, Ohio--( BUSINESS WIRE )-- ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ) recently filed for patent protection for a new application of its AAGP® molecule. During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP®